Perrigo Company plc Stock News

Perrigo Company plc (PRGO) shares closed today at 0.1% above its 52 week low of $37.44, giving the company a market cap of $5B. The stock is currently down 14.1% year-to-date, down 20.0% over the past 12 months, and down 54.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 56.5% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1197.5% The company's stock price performance over the past 12 months lags the peer average by -344.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Perrigo Company plc (NYSE:PRGO)s share price reached a new 52-week low on Friday . The company traded as low as $38.19 and last traded at $38.23, with a volume of 1909 shares traded. The stock had previously closed at $38.83. A number of analysts recently weighed in on the stock. Raymond James reduced their price []

The Keloid Treatment Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. This market report provides a holistic scope of the market which includes future supply and demand

Analysts expect that Perrigo Company plc (NYSE:PRGO) will report sales of $1.09 billion for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Perrigos earnings. The highest sales estimate is $1.12 billion and the lowest is $1.07 billion. Perrigo reported sales of $1.29 billion during the same quarter last year, which indicates []

Related Stocks: SON , KRE , PRGO , CDK , IJR , TLT ,

This Gamma-Aminobutyric Acid (GABA) Receptor market report is based on data collected from industry professionals and market analysts across the entire chain. The end-user industry analysis depicted here assists key stakeholders in making critical decisions. The worldwide market is segmented

Related Stocks: CNNE , XLE , AMLP , UBER , PRGO , GE , GLPG , SC , BLUE ,

Balyasny Asset Management LLC cut its holdings in Perrigo Company plc (NYSE:PRGO) by 90.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,390 shares of the companys stock after selling 156,223 shares during the quarter. Balyasny Asset Management LLCs holdings []

A couple of months back we discussed that Perrigo stock, a private label over-the-counter pharmaceuticals company, may see lower levels, based on the Trefis machine learning engine, which analyzes his

Rising costs make a tough business even tougher to turn a profit.

Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2021 results - Earnings Call Transcript

Perrigo (PRGO) reports dismal third-quarter 2021 results. Stock declines.

Perrigo (PRGO) delivered earnings and revenue surprises of -30.77% and -0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Perrigo Plc PRGO, -1.00% , the Dublin-based consumer self-care products maker, posted weaker-than-expected third-quarter earnings on Wednesday and issued a profit warning for the full year, after the